NeurologyLive Friday 5 — August 7, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Risdiplam Approved as First Oral Treatment for SMA
The agent, marketed under the brand name Evrysdi, is the first at-home therapy indicated for treatment of adults and children with SMA types 1, 2, or 3.
2: FDA Accepts Aducanumab for Review as Alzheimer Disease Treatment
A PDUFA date has been scheduled for March 7, 2021, but the agency said it would consider an even more expedited review if warranted..
3: Tweet Chat Highlights: Mental Health in Neurology
An overview of the tweet chat from NeurologyLive and the Women Neurologists Group on mental health in neurological disorders, featuring highlighted contributions from the medical community.
4: Hubert Fernandez, MD: Therapeutic Innovations For Parkinson Disease
The director of the Center for Neurological Restoration at Cleveland Clinic detailed the recent technological and therapeutic innovations and their advantages in treating Parkinson disease.
5: Shai Efrati, MD: Progression of Hyperbaric Oxygen Therapy for Neurodegeneration
The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed the history of the research and offered insight into the attempt to regenerate injured tissue in the brain.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
Pathophysiology of Myasthenia GravisSeptember 18th 2025
